For example, the introduction of an anti-CD133 Ab has been a pivot for targeted treatment against cancer, as the cell surface marker CD133 (prominin-1) has been identified in various types of cancers, such as brain, prostate, and colorectal cancer. This evidence concerns the gene PROM1 and cancer.